Literature DB >> 32082896

Simultaneous resection of thymic and bronchial carcinoid tumors in a patient diagnosed with multiple endocrine neoplasia type 1.

Ulaş Kumbasar1, Süleyman Nahit Şendur2, Yiğit Yılmaz1, Tomris Erbaş3, Sevgen Önder4, Rıza Doğan1.   

Abstract

Thymic carcinoid tumors are rare tumors which may be associated with multiple endocrine neoplasia type 1. Bronchial carcinoids are also rare tumors and associated with multiple endocrine neoplasia type 1. Coexisting of thymic and bronchial carcinoid tumors in this case is extremely rare. Herein, we report a unique case of coexistence of thymic and bronchial carcinoid tumors which were simultaneously resected via thoracotomy.
Copyright © 2019, Turkish Society of Cardiovascular Surgery.

Entities:  

Keywords:  Carcinoid tumor; multiple endocrine neoplasia type 1; resection

Year:  2019        PMID： 32082896      PMCID： PMC7021414          DOI： 10.5606/tgkdc.dergisi.2019.17748

Source DB:  PubMed          Journal:  Turk Gogus Kalp Damar Cerrahisi Derg        ISSN： 1301-5680            Impact factor:   0.332


  15 in total

Review 1.  A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria.

Authors:  Marcelo F Benveniste; Robert J Korst; Arun Rajan; Frank C Detterbeck; Edith M Marom
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

2.  Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1.

Authors:  Nirupa Sachithanandan; Robin A Harle; John R Burgess
Journal:  Cancer       Date:  2005-02-01       Impact factor: 6.860

3.  Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series.

Authors:  P Ferolla; A Falchetti; P Filosso; P Tomassetti; G Tamburrano; N Avenia; G Daddi; F Puma; R Ribacchi; F Santeusanio; G Angeletti; M L Brandi
Journal:  J Clin Endocrinol Metab       Date:  2005-02-15       Impact factor: 5.958

4.  Prediction of major cardiovascular events after lung resection using a modified scoring system.

Authors:  Mark K Ferguson; Paramita Saha-Chaudhuri; John D Mitchell; Gonzalo Varela; Alex Brunelli
Journal:  Ann Thorac Surg       Date:  2014-02-22       Impact factor: 4.330

5.  Synchronous thymoma and lung adenocarcinoma treated with a single mini-invasive approach.

Authors:  Giampiero Dolci; Andrea Dell'Amore; Nizar Asadi; Guido Caroli; Domenico Greco; Franco Stella; Alessandro Bini
Journal:  Heart Lung Circ       Date:  2014-09-02       Impact factor: 2.975

6.  Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1.

Authors:  Fathia Gibril; Yuan-Jia Chen; David S Schrump; Alexander Vortmeyer; Zhengping Zhuang; Irina A Lubensky; James C Reynolds; Adeline Louie; Laurence K Entsuah; Kane Huang; Behnam Asgharian; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

7.  The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized?

Authors:  J J Shepherd
Journal:  Arch Surg       Date:  1991-08

8.  Thymic and Bronchial Carcinoid Tumors in Multiple Endocrine Neoplasia Type 1: The Mayo Clinic Experience from 1977 to 2013.

Authors:  Naykky Singh Ospina; Geoffrey B Thompson; Francis C Nichols; Stephen D Cassivi; William F Young
Journal:  Horm Cancer       Date:  2015-06-13       Impact factor: 3.869

9.  Thymic carcinoid in a patient with multiple endocrine neoplasia type 1: report of a case.

Authors:  H Sugiura; T Morikawa; K Itoh; K Ono; S Okushiba; S Kondo; H Kato
Journal:  Surg Today       Date:  2001       Impact factor: 2.549

10.  Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients.

Authors:  Joanne M de Laat; Carolina R Pieterman; Medard F van den Broek; Jos W Twisk; Ad R Hermus; Olaf M Dekkers; Wouter W de Herder; Anouk N van der Horst-Schrivers; Madeleine L Drent; Peter H Bisschop; Bas Havekes; Menno R Vriens; Gerlof D Valk
Journal:  J Clin Endocrinol Metab       Date:  2014-06-10       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.